OBJECTIVE: Fixed incentives have been largely unsuccessful in improving adherence to antiretroviral medication. Therefore, we evaluate whether small incentives based on behavioral economic theory can increase adherence to antiretroviral medication among treatment-mature adults in Kampala, Uganda. DESIGN: A randomized control trial design tests whether providing small incentives based on either attending timely clinic visits (intervention group 1) or achieving high medication adherence (intervention group 2) can increase antiretroviral adherence. Antiretroviral adherence is measured by medical event monitoring system (MEMS) caps. METHODS: Overall, 155 HIV-infected men and women age 19-78 were randomized into one of two intervention groups and received small prizes of US $1.50 awarded through a drawing conditional on either attending scheduled clinic appointments or achieving at least 90% antiretroviral adherence. The control group received the usual standard of care. RESULTS: Preliminary results based on pooling the intervention groups showed individuals receiving incentives were 23.7 percentage points more likely to achieve 90% antiretroviral adherence compared with the control group [95% confidence interval (CI), 6.7-40.7%]. Specifically, 63.3% (95% CI, 52.9-72.8%) of participants in the pooled intervention groups maintained at least 90% mean adherence during the first 9 months of the intervention, compared with 39.6% (95% CI, 25.8-54.7%) in the control group. CONCLUSION: Small prize incentives resulted in a statistically significant increase in antiretroviral adherence. Although more traditional fixed incentives have not produced the desired results, these findings suggest that small incentives based on behavioral economic theory may be more effective in motivating long-term adherence among treatment-mature adults.
RCT Entities:
OBJECTIVE: Fixed incentives have been largely unsuccessful in improving adherence to antiretroviral medication. Therefore, we evaluate whether small incentives based on behavioral economic theory can increase adherence to antiretroviral medication among treatment-mature adults in Kampala, Uganda. DESIGN: A randomized control trial design tests whether providing small incentives based on either attending timely clinic visits (intervention group 1) or achieving high medication adherence (intervention group 2) can increase antiretroviral adherence. Antiretroviral adherence is measured by medical event monitoring system (MEMS) caps. METHODS: Overall, 155 HIV-infectedmen and women age 19-78 were randomized into one of two intervention groups and received small prizes of US $1.50 awarded through a drawing conditional on either attending scheduled clinic appointments or achieving at least 90% antiretroviral adherence. The control group received the usual standard of care. RESULTS: Preliminary results based on pooling the intervention groups showed individuals receiving incentives were 23.7 percentage points more likely to achieve 90% antiretroviral adherence compared with the control group [95% confidence interval (CI), 6.7-40.7%]. Specifically, 63.3% (95% CI, 52.9-72.8%) of participants in the pooled intervention groups maintained at least 90% mean adherence during the first 9 months of the intervention, compared with 39.6% (95% CI, 25.8-54.7%) in the control group. CONCLUSION: Small prize incentives resulted in a statistically significant increase in antiretroviral adherence. Although more traditional fixed incentives have not produced the desired results, these findings suggest that small incentives based on behavioral economic theory may be more effective in motivating long-term adherence among treatment-mature adults.
Authors: Jonathan Mermin; John Lule; John Paul Ekwaru; Samuel Malamba; Robert Downing; Ray Ransom; Frank Kaharuza; David Culver; Francis Kizito; Rebecca Bunnell; Aminah Kigozi; Damalie Nakanjako; Winnie Wafula; Robert Quick Journal: Lancet Date: 2004 Oct 16-22 Impact factor: 79.321
Authors: Jeonnette R Ickovics; Ann Cameron; Robert Zackin; Roland Bassett; Margaret Chesney; Victoria A Johnson; Daniel R Kuritzkes Journal: Antivir Ther Date: 2002-09
Authors: Damien de Walque; William H Dow; Rose Nathan; Ramadhani Abdul; Faraji Abilahi; Erick Gong; Zachary Isdahl; Julian Jamison; Boniphace Jullu; Suneeta Krishnan; Albert Majura; Edward Miguel; Jeanne Moncada; Sally Mtenga; Mathew Alexander Mwanyangala; Laura Packel; Julius Schachter; Kizito Shirima; Carol A Medlin Journal: BMJ Open Date: 2012-02-08 Impact factor: 3.006
Authors: Kevin G Volpp; George Loewenstein; Andrea B Troxel; Jalpa Doshi; Maureen Price; Mitchell Laskin; Stephen E Kimmel Journal: BMC Health Serv Res Date: 2008-12-23 Impact factor: 2.655
Authors: Maria L Ekstrand; Elsa Heylen; Matilda Pereira; Jacob D'Souza; Shoba Nair; Amanda Mazur; Ranjani Shamsundar; B N Ravi Kumar; Sara Chandy Journal: AIDS Behav Date: 2020-07
Authors: Tamsin K Phillips; Kemberlee Bonnet; Landon Myer; Sizakele Buthelezi; Zanele Rini; Jean Bassett; David Schlundt; Kate Clouse Journal: Matern Child Health J Date: 2019-09
Authors: Tamar Krishnamurti; Kimberly Ling Murtaugh; Lara Van Nunen; Alexander L Davis; Jonathan Ipser; Steven Shoptaw Journal: J Subst Abuse Treat Date: 2020-01-25
Authors: Anjuli D Wagner; Seema K Shah; Irene N Njuguna; Kathryn M Porter; Jillian Neary; Elizabeth Maleche-Obimbo; Rose Bosire; Dalton C Wamalwa; Grace C John-Stewart; Jennifer A Slyker Journal: J Acquir Immune Defic Syndr Date: 2018-07-01 Impact factor: 3.731
Authors: Carolyn A Fahey; Prosper F Njau; Emmanuel Katabaro; Rashid S Mfaume; Nzovu Ulenga; Natalino Mwenda; Patrick T Bradshaw; William H Dow; Nancy S Padian; Nicholas P Jewell; Sandra I McCoy Journal: Lancet HIV Date: 2020-09-03 Impact factor: 12.767